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INTRODUCTION
Mixed goblet cell carcinoid-adenocarcinoma (GCC) tumors are a group of rare
heterogeneous neoplasms of the appendix first described in 1969 by Gagne et al
that account for < 5% of all primary appendiceal tumors.1,2 These hybrid tumors
are characterized as an intermediate between classic carcinoid tumors and
appendiceal adenocarcinomas, exhibiting both neuroendocrine and
glandular/mucinous morphology that most commonly presents in Caucasian
females in the fifth and sixth decades.1,3–6 Their distinct glandular and
neuroendocrine differentiation has led to multiple names and designations
including adenocarcinoids, mucinous-carcinoid, mixed carcinoid-adenocarcinoma,
microglandular goblet cell carcinoma, and crypt cell adenocarcinoma.7 A broader
classification system has been suggested for GCC tumors based on their histologic
appearance.3 The system classifies the tumors into 3 sub-groups: typical goblet
cell carcinoid (Group A), adenocarcinoma ex-goblet cell carcinoid; signet-ring cell
type (group B), and adenocarcinoma ex-goblet cell carcinoid; poorly differentiated
carcinoma type (group C).3 The most common presentation for GCC tumors is
acute appendicitis.3,8 We present three cases of mixed goblet cell carcinoidadenocarcinoma presenting as acute appendicitis.

CASE PRESENTATIONS
Case #1 involved a 65-year-old male who presented with right lower quadrant
pain, nausea, emesis, and leukocytosis. A CT scan of the abdomen revealed
perforated appendicitis. The patient underwent a laparoscopic appendectomy.
Pathology revealed a high-grade adenocarcinoma ex goblet cell carcinoid, signet
ring type extending through the muscularis propria and into the mesoappendix
measuring >3cm. The patient subsequently underwent a colonoscopy that
revealed diverticulosis involving the sigmoid colon, but was otherwise normal.
Labs revealed that CEA, CA-125, and chromogranin A were negative. Patient then
underwent an exploratory laparotomy with a right hemicolectomy and partial
omentectomy. Pathology revealed normal ileal and colonic mucosa without
evidence of carcinoma. Omental specimen showed no evidence of metastatic
carcinoma. 0/12 nodes were positive for metastatic carcinoma.

Image 1. CT imaging displaying acute
appendicitis

Table 1. TNM Staging of Mixed Goblet Cell
Carcinoid-Adenocarcinoma
Image 2. H & E stain demonstrating clusters of goblet cells invading
the muscular wall of the appendix as seen in Group A mixed goblet
cell carcinoid-adenocarcinoma12
Case #2 involved a 49-year-old male who presented with periumbilical pain,
nausea, emesis, and leukocytosis. A CT scan of the abdomen revealed
appendicitis. The patient underwent an uneventful laparoscopic appendectomy.
Pathology revealed a high-grade, poorly differentiated, adenocarcinoma ex
goblet cell carcinoid invading through the muscularis propria and into the
periappendiceal soft tissue measuring 1.5cm. The patient subsequently
underwent a colonoscopy that revealed diverticulosis involving the sigmoid
colon, but was otherwise normal. Patient then underwent an uneventful
laparoscopic right hemicolectomy. Pathology revealed normal ileal and colonic
mucosa without evidence of carcinoma. 0/14 nodes were positive for
metastatic carcinoma.
Case #3 involved a 70-year-old female who presented with periumbilical pain. A
CT scan of the abdomen revealed appendicitis. The patient underwent an
uneventful laparoscopic appendectomy. Pathology revealed a high-grade
adenocarcinoma ex goblet cell carcinoid extending through the muscularis
propria and into the mesoappendix measuring 4cm. Patient then underwent an
exploratory laparotomy with a right hemicolectomy. Pathology revealed normal
ileal and colonic mucosa without evidence of carcinoma. 0/21 nodes were
positive for metastatic carcinoma.

CONCLUSION
Mixed goblet cell carcinoid-adenocarcinoma tumors are rare tumors that tend to
present at an advanced stage with up to 40% positive lymphadenopathy and most
commonly spread via direct extension.8 Surgical resection with a right hemicolectomy after an appendectomy has been shown to improve the prognosis and
is thus recommended in most cases.9,10 HIPEC and adjuvant chemotherapy are
other therapeutic options, but have not been shown to improve survival.11 The
adjuvant chemotherapy recommended composes of 5-florouracil (5-FU), FOLFOX
(5-FU, leucovorin, and oxaliplatin), and FOLFIRI(5-FU, folic acid, and irinotecan).7,9
In the current age of increasing rates of managing acute appendicitis nonoperatively we strongly encourage surgical appendectomy in patients older than
45 years of age to avoid missing this important diagnosis and the opportunity to
treat it in a timely manner.
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